GSK's Potential Small-Cell Lung Cancer Drug Meets Primary Endpoint in Late-Stage Trial
MT Newswires Live
Yesterday
GSK (GSK) licensor Hansoh Pharmaceutical reported Sunday that a phase 3 trial evaluating risvutatug rezetecan, or Ris-Rez, against commonly used topotecan in patients with relapsed small-cell lung cancer met its primary endpoint.
Results of the trial showed the drug conjugate cut risk of death by 54% versus topotecan, the company said.
Patients treated with Ris-Rez lived a median of 18.5 months compared with 10.3 months for those treated with topotecan, the company added.
GSK retains exclusive rights to develop and commercialize Ris-Rez outside mainland China, Hong Kong, Macau and Taiwan, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.